Pyxis Oncology, Inc.

Healthcare

NASDAQ:PYXS · NASDAQ Global Select

Market Cap $128.61M Beta 1.43 P/E (TTM) -1.6

$2.03 +5.53%

+$0.11 today

52W Low $0.97High $5.55

Vol 0.63M · Avg 0.50M

EPS (TTM) -$1.29Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+67.77%

Period High

$5.34

Period Low

$1.04

Latest

$2.03

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

$346.92M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

$293.50M

Foghorn Therapeutics Inc.

NASDAQ:FHTX

$242.49M

Zura Bio Limited

NASDAQ:ZURA

$241.23M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

$224.47M

Immuneering Corporation

NASDAQ:IMRX

$159.68M

Caribou Biosciences, Inc.

NASDAQ:CRBU

$159.67M

Humacyte, Inc.

NASDAQ:HUMA

$156.59M

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

$117.84M

What is the latest PYXS filing?

The latest filing shown is 8-K dated Jun 15, 2026.

How many recent filings does PYXS have?

Intrinsic Alpha currently shows 20 recent filings for PYXS.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.